Missouri Medicaid (MO HealthNet) GLP-1 Coverage (2026): Pattern #22 — Affirmative Coverage with Wegovy Demoted to MACE/MASH-Only + Foundayo Preferred First in 22-State Series + Dual Federal Model LOIs

TL;DR — 5th positive-coverage state, Wegovy demoted, Foundayo first-in-series

MO HealthNet (Missouri Medicaid) covers GLP-1 receptor agonists for chronic weight management, making it one of 13 states KFF classified as covering GLP-1s for obesity treatment as of January 2026. But Missouri’s structure is uniquely asymmetric: Zepbound (tirzepatide) and Foundayo (orforglipron) are Preferred with prior authorization, while Wegovy (semaglutide) is explicitly excluded from chronic weight management and restricted to two FDA-anchored cardiometabolic indications only.

The PA Form 2575-053 (January 2026) states verbatim: “Wegovy for the reduction of excess body weight or maintenance of weight reduction long term is not covered by MO HealthNet.” Missouri is the only positive-coverage state in this 22-state series where Wegovy CWM is verbatim excluded.

Foundayo (orforglipron, Lilly’s oral GLP-1) appears as Preferred on the 2026-05-01 Uniform PDL — making Missouri the first state Medicaid program in this series to formally place orforglipron on a preferred PDL class. Coverage launched January 9, 2025. No hostile 2026 legislation targets MO HealthNet GLP-1 coverage. In January 2026, Missouri submitted Letters of Intent to join both the CMMI BALANCE Model and the GENEROUS Most Favored Nation pricing model — the only state in this series to submit LOIs to both simultaneously.

Pattern #22 in the 50-state series — where Missouri fits

Missouri is the 22nd state analyzed in this 50-state Medicaid GLP-1 series and the 5th state with positive obesity-indication coverage (following NC #10, VA #18, WI #19, and TN #13 as positive-coverage states). Its pattern is the most structurally distinctive of the five:

• NC (#10 — Double Reversal): Wegovy is Preferred for chronic weight management; coverage was terminated October 2025 and reinstated December 2025. NC lists Wegovy as the primary preferred anti-obesity GLP-1 — the opposite of Missouri’s Wegovy demotion.
• TN (#13 — Affirmative Expansion): Broadest AOM panel in the series; both Wegovy and Zepbound are Preferred for CWM via formal rulemaking (Sequence 10-34-25, August 1, 2025). TN is the only other positive-coverage state with Zepbound Preferred alongside Wegovy. Missouri has Zepbound Preferred but Wegovy explicitly excluded for CWM.
• VA (#18 — Conditional Coverage): Covers Wegovy and Zepbound for weight management only at BMI > 40, with two-level step therapy. Missouri has no such elevated BMI floor for Zepbound (BMI ≥ 30 with no comorbidities suffices).
• WI (#19 — Restrictive Cap): Positive coverage since March 2023 with a 2-lifetime-attempts cap per drug and a BMI < 24 renewal-revocation rule. Missouri has no lifetime-attempt cap and no BMI-floor renewal-revocation.
• MN (#20 — Dedicated Weight Management Agents Class): Minnesota’s PDL has a dedicated “Weight Management Agents” class with Saxenda and Wegovy as Preferred — the structural inverse of Missouri. MN lists Zepbound Non-Preferred; Missouri lists Zepbound Preferred. MN lists Wegovy Preferred; Missouri excludes Wegovy for CWM.

Missouri’s defining structural features in the series taxonomy:

1. First to list orforglipron (Foundayo) as Preferred in the 22-state taxonomy — reflects the quarterly DPAC cycle capturing Foundayo in the October 2025 review window, within weeks of its November 2025 FDA approval.
2. Only positive-coverage state where Wegovy CWM is verbatim excluded — the PA form sentence is a primary-source operative exclusion, not a formulary absence.
3. First and only state to submit LOIs to both BALANCE and GENEROUS — documented in the January 20, 2026 DPAC minutes.
4. Dual-vendor PBM structure (Conduent SmartPA + Gainwell PDL) — the only state in the series where clinical-edit drafting and PDL-preferred-classification are handled by independent vendors under separate contracts.
5. Statewide pharmacy carve-out from all MCOs since 2009 — the most durable MCO-bypass structure in the series.

Missouri does NOT have a regulatory weight-loss-drug exclusion in 13 CSR 70-20.200. All GLP-1 coverage decisions are operational (SmartPA criteria, PDL placement), meaning they can be reversed or expanded at any quarterly DPAC meeting without legislative or regulatory amendment — a structural agility that explains how Missouri added Foundayo to Preferred within months of the FDA approval and how Missouri could, in theory, restore Wegovy CWM at a future October quarterly meeting.

Wegovy is verbatim NOT covered for chronic weight management in Missouri

PA Form 2575-053 (January 2026) — the operationally-binding fax-submission instrument for all MO HealthNet GLP-1 prior authorizations — contains a verbatim exclusion sentence that appears directly above the Wegovy MACE and MASH checkbox sections:

“Wegovy for the reduction of excess body weight or maintenance of weight reduction long term is not covered by MO HealthNet.”
— PA Form 2575-053, January 2026, MO HealthNet Division

The SmartPA Criteria Proposal (October 14, 2025) establishes the regulatory basis for this exclusion. Under the Approval Criteria, the Wegovy pathway appears as a mutually-exclusive branch to the BMI threshold pathway:

“For participants ≥ 18 years of age – must meet one of the following: Documented participant baseline BMI ≥ 30 kg/m²; Documented participant baseline BMI ≥ 27 kg/m² with documentation of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease); OR Claim is for Wegovy: [MACE criteria or MASH criteria only].”
— SmartPA Criteria, GLP-1 Receptor Agonists Indicated for Obesity PDL Edit, October 14, 2025

The structural consequence is that the BMI-threshold pathway (BMI ≥ 30 or BMI ≥ 27 + comorbidity) applies only to preferred agents (Zepbound, Zepbound KwikPen, Foundayo). Wegovy claims submitted under the BMI-threshold pathway will deny at the pharmacy with SmartPA Exception Code “0160” (Preferred Drug List), regardless of the prescribing physician’s intent.

The federal authority for this partial invocation is 42 U.S.C. § 1396r-8(d)(2)(A), which provides:

“The following drugs or classes of drugs, or their medical uses, may be excluded from coverage or otherwise restricted: (A) Agents when used for anorexia, weight loss, or weight gain.”
— 42 U.S.C. § 1396r-8(d)(2)(A)

Missouri has partially exercised this permissive exclusion: it has excluded semaglutide (Wegovy) for weight loss while affirmatively covering tirzepatide (Zepbound) and orforglipron (Foundayo) for weight loss under the same federal statute. This is doctrinally consistent because the exclusion is drug-specific, not indication-class-specific.

YMYL note for prescribers and patients: Missouri-resident MO HealthNet members and prescribers who default to Wegovy because it is the most-marketed semaglutide-for-weight-loss product will receive a SmartPA denial. The correct pathway for CWM in MO HealthNet is Zepbound or Foundayo, not Wegovy. Articles or prior-authorization resources published before May 2026 may operate from the 2024 PDL Edit framework in which Wegovy was still a CWM-covered option — this changed with the October 14, 2025 revision (first implementation January 9, 2025).

Wegovy retained for MACE and MASH: the two covered pathways

Although Wegovy is excluded from chronic weight management, MO HealthNet retains Wegovy coverage for two FDA-anchored cardiometabolic indications. PA Form 2575-053 documents both pathways verbatim.

Pathway 1: MACE risk reduction

“☐ Reduction of the risk major adverse cardiovascular events (MACE)
☐ Lack of diagnosis of diabetes as evidenced by documented Hemoglobin A1C within past 3 months < 6.5 demonstrating lack of diabetes mellitus and lack of history of any anti-diabetic pharmaceutical therapy attached
☐ Documentation indicating participant is ≥ 45 years of age and has a BMI ≥ 27 kg/m² attached
☐ Choose the participant’s diagnosis and submit documentation of one (1) of the below:
    ☐ Myocardial infarction
    ☐ Stroke
    ☐ Symptomatic peripheral arterial disease, as evidenced by one of the following:
        Intermittent claudication with ABI < 0.85 (at rest);
        Peripheral arterial revascularization procedure; OR
        Amputation due to ASCVD
☐ Documentation of all current medications for the diagnosis listed above attached”
— PA Form 2575-053, January 2026, MO HealthNet Division

This maps to Wegovy’s August 2024 FDA-approved cardiovascular risk reduction indication, anchored to the SELECT trial (Lincoff AM et al.,NEJM, 2023, PMID 37952131), which demonstrated a 20% relative risk reduction in MACE in adults with established CVD and overweight or obesity without diabetes.

Missouri’s MACE criteria add an age floor of ≥ 45 years and require A1C < 6.5 with no anti-diabetic pharmaceutical therapy in the past 2 years — confirming non-diabetic status. These requirements align with the SELECT trial eligibility criteria and mirror the MACE pathway structures in NY, OH, and CA, though Missouri’s BMI ≥ 27 threshold is the FDA-label minimum (the same as Kentucky’s, more permissive than NY’s BMI ≥ 40).

Wegovy MACE approvals carry a 4-week-only initial approval, with 4-week increments required per dose during titration until maintenance dose of at least 1.7 mg is reached:

“Initial approval for Wegovy is for four (4) weeks only. Subsequent approvals will be required for each dose during the titration process. All approvals will be for only four (4) weeks to allow for monitoring of proper dose escalation until maintenance therapy dosing is achieved (at least 1.7 mg/dose). An additional four (4) weeks for each dose in the titration process may be approved one time with documentation of intolerable adverse effects during dose escalation.”
— PA Form 2575-053, January 2026, MO HealthNet Division

Pathway 2: Noncirrhotic MASH with F2/F3 fibrosis

“☐ Noncirrhotic metabolic dysfunction associated steatohepatitis (MASH) demonstrating F2 or F3 fibrosis
☐ Recent liver biopsy or noninvasive techniques confirming diagnosis attached
☐ Lack of diagnosis of diabetes as evidenced by documented Hemoglobin A1C within past 3 months < 6.5 demonstrating lack of diabetes mellitus and lack of history of any anti-diabetic pharmaceutical therapy attached”
— PA Form 2575-053, January 2026, MO HealthNet Division

This maps to Wegovy’s August 15, 2025 FDA-approved indication for noncirrhotic MASH with moderate to advanced liver fibrosis, anchored to the ESSENCE trial (Newsome PN et al., NEJM, 2025, PMID 40305701). The MASH pathway requires biopsy or noninvasive confirmation of F2 or F3 fibrosis, current liver function tests, and gastroenterologist or hepatologist consultation — a specialist access gate that narrows the eligible population to patients with documented, staged MASH disease.

Together, the MACE and MASH pathways represent a deliberate indication-anchored carve-out within Missouri’s affirmative-coverage architecture: the federal 42 U.S.C. § 1396r-8(d)(2)(A) optional exclusion does not reach Wegovy’s MACE and MASH indications because those indications are not “agents when used for anorexia, weight loss, or weight gain” — they are cardiovascular and hepatic indications with weight loss as a secondary benefit.

Foundayo (orforglipron) Preferred — first state in the series

The 2026-05-01 MO HealthNet Uniform PDL — the most recently published PDL static document as of 2026-05-10 — lists the “Antihyperglycemic, GLP-1 Receptor Agonists Indicated for Obesity” sub-class as:

“Class: Antihyperglycemic
Sub-Class: GLP-1 Receptor Agonists Indicated for Obesity
Review Date: October

Preferred Drugs          | Non-Preferred Drugs
Foundayo                | Wegovy
Zepbound                |
Zepbound KwikPen      |”
— MO HealthNet Uniform PDL, effective 2026-05-01

Foundayo is orforglipron, an oral, non-peptide GLP-1 receptor agonist developed by Eli Lilly, FDA-approved in November 2025 for chronic weight management in adults with obesity (BMI ≥ 30) or overweight (BMI ≥ 27) with at least one weight-related comorbidity. Unlike Zepbound (subcutaneous weekly injection) and Wegovy (subcutaneous weekly injection), Foundayo is a once-daily oral tablet — eliminating injection-related barriers.

Missouri’s DPAC holds quarterly reviews in October, January, April, and July. The October 14, 2025 DPAC meeting — which approved the Zepbound/Wegovy PDL edit revision — captured Foundayo review within the same cycle window that coincided with the FDA approval timeline. The 2026-05-01 PDL static document reflects Foundayo at Preferred status, making Missouri the first state Medicaid program in this 22-state series to formally list orforglipron on a preferred PDL class.

Practical note for prescribers (May 2026): PA Form 2575-053 (January 2026) was published before the 2026-05-01 PDL revision and does not yet include a Foundayo checkbox. Prescribers submitting Foundayo PAs should reference the 2026-05-01 PDL as authority. MO HealthNet is expected to update Form 2575-053 in Q3 2026 to include a Foundayo-specific checkbox. As of 2026-05-10, Foundayo-specific PA criteria have [NOT VERIFIED — call MO HealthNet Pharmacy Help Desk at (573) 751-6963 to confirm] whether PA criteria are identical to Zepbound’s or carry different eligibility thresholds.

Zepbound for chronic weight management: verbatim PA criteria

Zepbound is the operationally-primary anti-obesity GLP-1 in MO HealthNet for chronic weight management. The SmartPA Criteria (October 14, 2025) designate Zepbound as the sole Preferred agent for the obesity PDL edit (Foundayo was added Preferred via the 2026-05-01 PDL revision; the SmartPA criteria document predates this). Verbatim approval criteria:

“Must meet all of the following:
• Participant is aged ≥ 12 years;
• Must meet one of the following:
    – Claim is for a preferred agent; OR
    – Reason of medical necessity as to why a preferred agent cannot be utilized; AND
• Must meet one of the following:
    – Documented compliance to current preferred agent therapy;
    – For participants < 18 years of age: Documented participant baseline BMI ≥ 95th percentile standardized for age and sex; OR
    – For participants ≥ 18 years of age – must meet one of the following:
        • Documented participant baseline BMI ≥ 30 kg/m²;
        • Documented participant baseline BMI ≥ 27 kg/m² with documentation of at least one weight-related comorbid condition (e.g., hypertension, dyslipidemia, obstructive sleep apnea, or cardiovascular disease)”
— SmartPA Criteria, GLP-1 Receptor Agonists Indicated for Obesity PDL Edit, October 14, 2025

These criteria are clinically permissive relative to other states in the series:

• No step-therapy requirement through a non-GLP-1 weight-loss drug before Zepbound.
• BMI ≥ 30 with no comorbidity required — the FDA-label minimum.
• BMI ≥ 27 + one comorbidity — also FDA-label minimum; the comorbidity list (hypertension, dyslipidemia, OSA, cardiovascular disease) is not exhaustive.
• No lifetime-attempt cap (unlike Wisconsin’s 2-attempt cap).
• No BMI-below-threshold renewal-revocation (unlike Wisconsin’s BMI < 24 renewal-revocation rule).

Verbatim denial criteria:

“Therapy will deny with presence of one of the following:
• Any approval criteria are not met;
• Concurrent therapy with another GLP-1 receptor agonist;
• For Wegovy: participant is unable to complete titration/dose escalation to at least 1.7 mg/dose within 6 months of beginning therapy; OR
• Claim exceeds maximum dosing limitation”
— SmartPA Criteria, GLP-1 Receptor Agonists Indicated for Obesity PDL Edit, October 14, 2025

Note that the concurrent-GLP-1-therapy denial criterion applies to Zepbound as well as Wegovy: a member already prescribed Ozempic or Trulicity for T2DM who is also prescribed Zepbound for CWM will deny at the point-of-sale.

Verbatim disposition of the SmartPA edit:

“Disposition of Edit: Denial: Exception Code ‘0160’ (Preferred Drug List); Rule Type: PDL
Default Approval Period: 1 year”
— SmartPA Criteria, GLP-1 Receptor Agonists Indicated for Obesity PDL Edit, October 14, 2025

Antipsychotic-induced weight gain: Zepbound’s unique first-listed indication in Missouri

PA Form 2575-053 (January 2026) lists the following indication checkboxes under Zepbound:

“Choose one (1) of the following and provide documentation as necessary:
☐ Concurrent therapy with an antipsychotic
☐ Participant is 12–17 years of age and BMI ≥ 95th percentile standardized for age and sex
☐ Participant is ≥ 18 years of age and BMI ≥ 30 kg/m²
☐ Participant is ≥ 18 years of age and BMI ≥ 27 kg/m² with documentation of at least one (1) weight-related comorbid condition. Submit supporting documentation.
☐ Participant is ≥ 18 years of age and has a diagnosis of metabolic dysfunction-associated steatohepatitis (MASH) demonstrating F2 or F3 fibrosis. Must submit recent liver biopsy or noninvasive techniques confirming diagnosis.”
— PA Form 2575-053, January 2026, MO HealthNet Division

The “Concurrent therapy with an antipsychotic” checkbox is the first-listed indication — placed before the BMI-threshold pathways. This is unique among the 22 states analyzed in this series: no other state’s PA form explicitly lists antipsychotic-induced weight gain as a standalone approved indication for a GLP-1 anti-obesity agent.

The clinical rationale is well-documented. Second-generation antipsychotics (SGAs) — including clozapine, olanzapine, risperidone, quetiapine, and aripiprazole — are associated with metabolic side effects including significant weight gain, insulin resistance, and dyslipidemia. Tirzepatide’s dual GIP/GLP-1 agonism provides weight-loss and metabolic benefits that may partially counteract SGA-induced metabolic burden.

Missouri’s community mental health infrastructure includes state-operated psychiatric centers serving individuals on long-term SGA therapy. The antipsychotic carve-out in the PA form reflects an operationally meaningful pathway: members on clozapine or olanzapine with clinically significant weight gain may qualify for Zepbound without meeting the standard BMI ≥ 30 or BMI ≥ 27 + comorbidity adult threshold criteria, as the antipsychotic indication checkbox is independent of the BMI pathway checkboxes.

YMYL framing: Prescribers who serve MO HealthNet members on long-term SGA therapy should be aware of this pathway. It does not appear in the October 14, 2025 SmartPA Criteria Proposal text in the same prominence as the BMI criteria — the PA form (Form 2575-053) is the operationally-binding instrument that makes the antipsychotic pathway explicit. There is no published MO HealthNet policy document specifying the minimum weight gain or BMI threshold required to trigger this pathway; prescribers should document clinically significant antipsychotic-induced weight gain in the PA submission.

Pediatric paradox: Wegovy on-label but excluded; Zepbound off-label but permitted for ages 12–17

Missouri’s Wegovy CWM exclusion creates a documented FDA-label-versus-state-coverage mismatch for adolescent patients:

• Wegovy (semaglutide): FDA-approved for adolescents 12–17 years with obesity (BMI ≥ 95th percentile), approved December 2022. This is an on-label use for adolescents. However, MO HealthNet’s verbatim exclusion — “Wegovy for the reduction of excess body weight or maintenance of weight reduction long term is not covered by MO HealthNet” — applies to all age groups, including adolescents. Unless the adolescent meets the MACE or MASH criteria (which require established cardiovascular disease or biopsy-confirmed liver fibrosis — clinically rare in 12–17-year-olds), Wegovy is not accessible through MO HealthNet for adolescent CWM.
• Zepbound (tirzepatide): FDA-approved for adults 18 and older only — Zepbound is not FDA-approved for pediatric use (12–17). However, MO HealthNet’s SmartPA criteria and PA Form 2575-053 explicitly permit prescribing Zepbound for adolescents 12–17 under the BMI ≥ 95th percentile pathway. This is an off-label use for adolescents. The Children’s Mercy newsletter (January 2025) acknowledged this directly:

“Tirzepatide (Zepbound®) is not yet FDA approved for children under the age of 18 and should be used with caution only in those under 18 years of age.”
— Hampl, Sarah MD and Sweeney, Brooke MD; State of the Art Pediatrics: A New Year for Obesity Treatment; Children’s Mercy Newsletter, January 2025

The structural inversion: the on-label pediatric obesity drug (Wegovy) is excluded by Missouri for chronic weight management, while the off-label pediatric use (Zepbound in 12–17-year-olds) is permitted under the PA framework. Prescribers who order Zepbound for adolescent MO HealthNet members accept clinical liability for off-label prescribing. Missouri does not appear to have published a prescriber guidance document specifically addressing this mismatch beyond the Children’s Mercy newsletter characterization.

The AAP 2023 Clinical Practice Guideline for the Evaluation and Treatment of Children and Adolescents With Obesity (Hampl SE et al., Pediatrics, 2023, cited in the SmartPA Criteria references) endorses pharmacotherapy including GLP-1 receptor agonists for adolescents with obesity. The SmartPA Criteria reference list includes this guideline as an evidence anchor for the pediatric BMI ≥ 95th percentile pathway.

What this means for families: A Missouri adolescent 12–17 with obesity and a pediatric prescriber who is comfortable with the off-label use may access Zepbound through MO HealthNet via Form 2575-053 with documentation of BMI ≥ 95th percentile. A prescriber seeking to use the FDA-on-label pediatric option (Wegovy) for chronic weight management will be denied by Missouri’s PDL. This article does not advocate for or against this clinical choice; it documents the operative coverage structure.

Dual federal model LOIs: BALANCE and GENEROUS — first state in the series to submit both

The January 20, 2026 DPAC meeting minutes include a Pharmacy Director’s Update by Olivia Geritz (MO HealthNet Program Integrity Pharmacist) with the following verbatim notation:

“MHD submitted Letters of Intent to join the CMMI BALANCE Model for GLP-1s and the GENEROUS Model for Most Favored Nation pricing”
— DPAC Meeting Minutes, January 20, 2026; Pharmacy Director’s Update, Olivia Geritz

Missouri is the only state in this 22-state series to have submitted Letters of Intent to both BALANCE and GENEROUS simultaneously. The two models address different aspects of GLP-1 access and pricing:

• CMMI BALANCE Model (December 23, 2025): A Centers for Medicare & Medicaid Services Innovation Center voluntary model designed to expand GLP-1 drug access in Medicaid. States that participate agree to use CMMI-negotiated pricing and implement evidence-based PA criteria across their Medicaid population.
• GENEROUS Model (November 2025): A Trump-administration Most Favored Nation (MFN) pricing arrangement with Eli Lilly and Novo Nordisk, designed to benchmark Medicaid drug prices to international reference prices. The arrangement targets the GLP-1 anti-obesity class directly and would, if participation materializes, reduce the per-member-per-month net cost of Foundayo, Zepbound, and Wegovy for Medicaid programs.

Critical YMYL hedge: An LOI is not equivalent to participation. CMS BALANCE has not yet announced state participants as of 2026-05-10. The GENEROUS arrangement’s participation mechanics are not yet publicly documented. This article does NOT predict that Missouri will join either model or predict any pricing or formulary changes resulting from participation. The LOI is documented as a January 2026 administrative action and no more.

The dual-LOI posture is structurally significant because it signals that MO HealthNet is actively monitoring both access-expansion and cost-reduction pathways for its GLP-1 program. Missouri entered 2026 as an already-covering state with an expanding formulary (Foundayo added Q4 2025 — Q1 2026 PDL revision), no hostile legislation, and dual federal-model LOIs — a configuration the prior 21 states in this series had not achieved.

Dual-vendor PBM architecture: Conduent SmartPA + Gainwell PDL

Missouri’s pharmacy benefit administration is split between two independent vendors — a structure found nowhere else in the 22-state series:

• Conduent Business Services, LLC — operates the Clinical Management and System for Pharmacy (CMSP), including the SmartPA point-of-sale prior-authorization engine and the Drug Prior Authorization Committee (DPAC) clinical-edit drafting workflow. Conduent SmartPA adjudicates GLP-1 claims at the pharmacy register in real time. When a Wegovy prescription is submitted for CWM at any Missouri pharmacy, SmartPA denies it immediately with Exception Code “0160” before a human reviewer sees the claim.
• Gainwell Technologies — provides PDL preferred/non-preferred classification, supplemental rebate negotiation, evidence-based therapeutic-class review, and the public-facing PDL searchable database at mopdl.gainwelltechnologies.com. Gainwell’s PDL team drafted the therapeutic-class review cited in the SmartPA Criteria references: “Therapeutic Class Review: ENDOCRINE AND METABOLIC AGENTS: Antihyperglycemic, GLP-1 Receptor Agonists for Overweight/Obesity, Gainwell Technologies; Last updated August 14, 2025.”

This dual-vendor split means clinical-edit drafting (Conduent) and PDL preferred-classification / rebate negotiation (Gainwell) are operationally independent. A structural advantage: conflicts of interest between clinical-edit drafting and supplemental-rebate-negotiation are reduced because the same vendor does not simultaneously draft clinical criteria and negotiate pricing with the manufacturers whose products those criteria govern. Missouri is structurally most similar to Ohio (which also uses Gainwell for part of its pharmacy infrastructure) but unique in the dual-vendor independence of clinical and PDL functions.

Both Conduent and Gainwell staff attended the January 20, 2026 DPAC meeting. The minutes list the following Conduent staff: Aissa Sayles, John Crowley, John Dolan, Linh Morsches; and the following Gainwell staff: Amanda Williams, Amy Hartmann, Annie Carter, Bobby Varghese, Brandon Schowengerdt, Chris Brown, Jovanna Leid, Megan Fast, Sandy Kapur, Serena Barden, Vicki Revel, Yogi Patel.

For GLP-1 prior authorization questions:

• PA submission fax: (573) 636-6470 (PA Form 2575-053)
• MO HealthNet Pharmacy Help Desk: (573) 751-6963
• Drug-specific questions: (800) 392-8030
• Member pharmacy services: (800) 392-2161
• PDL lookup: mopdl.gainwelltechnologies.com

Coverage launched January 9, 2025 — historical record

MO HealthNet’s GLP-1 obesity coverage commenced on January 9, 2025, per the SmartPA Criteria Proposal’s verbatim document header:

“SmartPA Criteria Proposal
Drug/Drug Class: Glucagon-Like Peptide-1 (GLP-1) Receptor Agonists Indicated for Obesity PDL Edit
First Implementation Date: January 9, 2025
Proposed Date: October 14, 2025
Prepared For: MO HealthNet
Prepared By: MO HealthNet/Conduent
Criteria Status: Revision of Existing Criteria”
— SmartPA Criteria Proposal, GLP-1 Receptor Agonists Indicated for Obesity PDL Edit, October 14, 2025 revision

The Children’s Mercy January 2025 newsletter confirms the launch date contemporaneously:

“As of this month, MO HealthNet’s Pharmacy will begin covering certain formulations [of GLP-1 medications].”

“MO HealthNet was noted as being one of the first state Medicaid systems to expand coverage of these obesity medications.”
— Hampl, Sarah MD and Sweeney, Brooke MD; State of the Art Pediatrics: A New Year for Obesity Treatment; Children’s Mercy Newsletter, January 2025

The “Criteria Status: Revision of Existing Criteria” notation on the October 2025 document means the October 2025 proposal revised the original January 2025 criteria (the 2024 PDL Edit from the October 15, 2024 DPAC meeting). The 2024 PDL Edit included Wegovy in the chronic-weight-management indication; the 2025 revision removed it. Missouri’s coverage trajectory has therefore been: January 9, 2025 (Zepbound + Wegovy CWM) → January 9, 2025 revision effective date (Zepbound preferred, Wegovy demoted to MACE/MASH only) → 2026-05-01 PDL (Foundayo added Preferred). Trajectory: expanding access for tirzepatide and orforglipron; contracting access for semaglutide (chronic weight management).

Statewide pharmacy carve-out from all three MCOs since October 1, 2009

Missouri’s pharmacy benefit has been statewide carved out of all MCO contracts since October 1, 2009. The carve-out was reaffirmed in the FY 2023 budget cycle. UnitedHealthcare Community Plan of Missouri’s provider documentation states verbatim:

“Missouri Medicaid members receive pharmacy benefits through the State’s MO HealthNet Fee-for-Service Pharmacy program, and the pharmacy benefit is not administered by the managed care plan.”
— UnitedHealthcare Community Plan of Missouri Provider Documentation

The three MO HealthNet Managed Care Organizations — Healthy Blue (Missouri Care, Inc., a Wellpoint/Anthem subsidiary), Home State Health (Centene), and UnitedHealthcare Community Plan of Missouri — each defer entirely to MO HealthNet FFS for pharmacy benefits. This means:

• The PDL is uniform statewide for all ~1 million MO HealthNet enrollees, regardless of MCO assignment.
• GLP-1 PA forms go to MO HealthNet (Form 2575-053, fax (573) 636-6470), NOT to Healthy Blue, Home State Health, or UnitedHealthcare.
• PA denials are appealed through the State Fair Hearing pathway, NOT through MCO internal appeals.
• There is no formulary shopping between MCOs for GLP-1 access — unlike MN, VA, TN, and most other states in this series where each MCO operates its own formulary.

The Minnesota House 2024 carve-out comparison study reported Missouri’s pharmacy carve-out generating approximately $4.4 million in state savings, and identified Missouri as one of eight statewide pharmacy-carve-out states as of July 1, 2023.

SB 1606: commercial-market pediatric obesity coverage, not MO HealthNet

Missouri’s 2026 legislative session includes one GLP-1-adjacent bill: SB 1606 (Sen. Patty Lewis, D-7). The verbatim bill title and operative section:

“AN ACT to amend chapter 376, RSMo, by adding thereto one new section relating to insurance coverage for treatment of obesity of certain persons.”

“Each health carrier or health benefit plan that offers or issues health benefit plans that are delivered, issued for delivery, continued or renewed in this state on or after January 1, 2027, shall provide coverage for the treatment of obesity and severe obesity and the diseases and ailments caused by obesity in persons between the ages of two years old and twenty years old, including, but not limited to, intensive health behavior and lifestyle treatment, pharmacotherapy, and metabolic and bariatric surgery.”
— SB 1606, 103rd General Assembly, 2nd Regular Session, 2026; Sponsor: Sen. Patty Lewis (D-7); Status: Second Read and Referred S Insurance and Banking Committee

SB 1606 amends Chapter 376, RSMo (commercial insurance statute), NOT Chapter 208, RSMo (social services / MO HealthNet). The bill would mandate commercial group health plans to cover pediatric obesity treatment (ages 2–20), including pharmacotherapy (GLP-1s), effective January 1, 2027 if enacted. SB 1606 does not affect MO HealthNet GLP-1 coverage in any way.

No active 2026 Missouri Senate or House bill seeks to terminate, expand, or modify MO HealthNet GLP-1 coverage, per a direct search of the Senate bill list for the 103rd General Assembly, 2nd Regular Session (searched 2026-05-10). Missouri’s MO HealthNet GLP-1 coverage is anchored entirely in the PDL/SmartPA operational infrastructure and does not depend on legislation to expand or contract.

SB 1606 status as of 2026-05-10: Second Read and Referred to the Senate Insurance and Banking Committee. The Missouri legislative session adjourns May 15, 2026 per Missouri Constitution Article III § 20.

T2D versus weight-loss: two separate PDL classes with different pathways

MO HealthNet operates two distinct GLP-1 PDL sub-classes, and the distinction matters operationally:

A member with type 2 diabetes who is prescribed Mounjaro (tirzepatide for T2DM) is on the Diabetes PDL class pathway — Mounjaro is Preferred there. A member without T2DM who is prescribed Zepbound (tirzepatide for chronic weight management) is on the Obesity PDL class pathway — Zepbound is Preferred there. The same molecule (tirzepatide) appears in both PDL sub-classes under different brand names, approved through different FDA indications and different PA pathways. Concurrent therapy with both is denied by the SmartPA concurrent-GLP-1 criterion.

Comparison: the 5 positive-coverage states (NC, TN, WI, MN, MO)

Missouri is the most tirzepatide-and-orforglipron-forward state in the series — the only positive-coverage state that simultaneously demotes Wegovy for CWM, elevates Zepbound as Preferred, and elevates Foundayo as Preferred. MN is the structural inverse: Saxenda and Wegovy Preferred, Zepbound Non-Preferred, Foundayo absent. TN has the broadest overall AOM panel (Preferred for both Wegovy and Zepbound) but does not yet list Foundayo. NC is similar to TN on breadth but has a history of policy instability. WI is the most conservative positive-coverage state (2-attempt lifetime cap, BMI < 24 renewal-revocation).

Missouri in context of the 22-state series

Missouri shares structural features with several prior states while being distinctive on key dimensions:

• vs. NY (#3) and OH (#6): Both NY and OH carve out Wegovy for MACE on an explicit non-coverage baseline (the 1396r-8(d)(2)(A) exclusion is affirmatively invoked for CWM). Missouri has the same Wegovy MACE/MASH carve-in, but Missouri’s overall posture is affirmative CWM coverage for Zepbound and Foundayo — the opposite of NY’s and OH’s non-coverage baselines.
• vs. CA (#2): California terminated Wegovy and Zepbound for CWM January 1, 2026, then re-added Wegovy MASH only April 1, 2026. Missouri independently arrived at a Wegovy-MACE-and-MASH-only structure without the coverage-then-termination sequence. The end-state for Wegovy is similar (non-CWM); the path is different.
• vs. PA (#7): Pennsylvania terminated CWM coverage January 1, 2026 after 34 months. Missouri began CWM coverage January 9, 2025 and has since expanded (Foundayo added, LOIs submitted). The trajectories are opposite.
• vs. WA (#14): Washington covers Wegovy MACE + MASH and Zepbound OSA via indication-anchored pathways layered on an explicit weight-loss regulatory exclusion (WAC 182-530-2100(1)(b)(i)). Missouri has no weight-loss regulatory exclusion in 13 CSR 70-20.200. Missouri covers Zepbound and Foundayo for CWM; WA does not.
• vs. TX (#1), FL (#4), IL (#5), GA (#8), AZ (#12), IN (#16): All are explicit non-coverage states. Missouri is structurally on the opposite side of the national divide.

The absence of a regulatory weight-loss-drug exclusion in 13 CSR 70-20.200 is structurally significant: Missouri’s Wegovy CWM exclusion is an operational PDL/SmartPA decision that can be reversed at any quarterly DPAC meeting. In contrast, WA, IL, MD, and IN have regulatory-level exclusions that require formal rulemaking to repeal. Missouri’s policy architecture is both more flexible to expand (Foundayo added without rulemaking) and more vulnerable to contraction (a future DPAC vote could remove Zepbound from Preferred without legislative action).

Populations not covered under current MO HealthNet structure

• Adults seeking Wegovy for chronic weight management — regardless of BMI, age, or comorbidities other than MACE/MASH eligibility. The PA form’s verbatim exclusion applies universally.
• Adults with type 2 diabetes seeking an obesity-class GLP-1 — members with T2DM are categorically excluded from both Wegovy MACE and MASH pathways (both require A1C < 6.5 and no anti-diabetic therapy history). T2DM members are routed to the Diabetes-class GLP-1 PDL pathway.
• Adolescents 12–17 seeking Wegovy for CWM — Wegovy’s FDA approval for ages 12–17 is not recognized by MO HealthNet for chronic weight management; these patients must use the off-label Zepbound pathway.
• Dual-eligible (Medicare + Medicaid) members for Zepbound CWM under Medicare Part D — Medicare Part D covers GLP-1s for CWM beginning July 1, 2026 under the CMS Medicare GLP-1 Bridge. Dual-eligibles who are auto-switched to Part D for Part D drugs are NOT covered for Zepbound CWM under Medicare Part D prior to July 1, 2026.
• Medications indicated only for anti-obesity not listed within the PDL: Per the SmartPA Criteria verbatim: “Medications indicated only for anti-obesity but not listed within this policy remain excluded from MO HealthNet coverage.” This would apply to any future anti-obesity agents not yet reviewed by DPAC.
• Saxenda (liraglutide for obesity): Not listed on the 2026-05-01 PDL under the Obesity sub-class. Its status is excluded by absence. Liraglutide (generic Victoza) is on the Diabetes Non-Preferred class.

Patient action steps and appeal pathway

Step 1: Confirm your MCO does NOT handle your pharmacy benefit

If you are enrolled in Healthy Blue, Home State Health, or UnitedHealthcare Community Plan, do NOT call those plans for GLP-1 prior authorization. Call the MO HealthNet Pharmacy Help Desk at (573) 751-6963 or (800) 392-8030 for drug-specific questions.

Step 2: Confirm which drug your prescriber is requesting

If your prescriber has written Wegovy for chronic weight management, the prescription will deny at the pharmacy. Ask your prescriber to switch to Zepbound or Foundayo — both are Preferred on the current PDL. If Wegovy is being requested for MACE or MASH, confirm your prescriber has the clinical documentation needed for the PA form (A1C < 6.5, prior MI/stroke/PAD documentation, or biopsy/LFT results for MASH).

Step 3: Submit PA Form 2575-053

Download PA Form 2575-053 from mydss.mo.gov. Complete the relevant indication section (Zepbound: BMI documentation; Wegovy: MACE or MASH documentation). Fax to (573) 636-6470. For Foundayo, reference the 2026-05-01 PDL preferred status in the submission; the form does not yet have a Foundayo checkbox (as of 2026-05-10).

Step 4: If denied, request a State Fair Hearing

You have 120 days from the denial notice to request a State Fair Hearing. Contact:

• Phone: (800) 392-2161 or (573) 751-6527 (TDD: 800-735-2966)
• Fax: (855) 860-9122
• Mail: MO HealthNet Division Constituent Services, Participant Services Unit, P.O. Box 6500, Jefferson City, MO 65102

The State will issue a written Administrative Law Judge decision within 90 days of the hearing request. You may bring a representative.

Step 5: If you are on antipsychotic therapy

Ask your prescriber about the concurrent-antipsychotic Zepbound pathway. This is a standalone indication on Form 2575-053 that may apply if you are currently prescribed a second-generation antipsychotic (clozapine, olanzapine, risperidone, quetiapine, aripiprazole) and have experienced clinically significant weight gain.

Related research

• North Carolina Medicaid GLP-1 coverage (2026): the double-reversal positive-coverage state — NC (Pattern #10) is the first positive-coverage state in the series and the structural counter-example to Missouri’s Wegovy demotion: NC lists Wegovy as Preferred for chronic weight management, while Missouri explicitly excludes it. Both are KFF-confirmed covering states, but with opposite Wegovy positioning.
• Tennessee Medicaid GLP-1 coverage (2026): Pattern #13 — broadest AOM panel, Wegovy + Zepbound both Preferred — TN (Pattern #13) has both Wegovy and Zepbound as Preferred for chronic weight management — the maximum-breadth positive-coverage posture among the five positive states. Missouri’s posture is the inverse: tirzepatide (Zepbound) and orforglipron (Foundayo) Preferred; semaglutide (Wegovy) excluded for CWM. TN is the most recently enacted via formal rulemaking (Sequence 10-34-25, August 1, 2025); Missouri operates through PDL/SmartPA operational change without legislative or regulatory amendment.
• Minnesota Medicaid GLP-1 coverage (2026): Pattern #20 — dedicated Weight Management Agents PDL class + active hostile HF4142 — MN (Pattern #20) is structurally the inverse of Missouri: MN lists Saxenda and Wegovy as Preferred; Zepbound as Non-Preferred; Foundayo absent. Missouri lists Zepbound and Foundayo as Preferred; Wegovy excluded for CWM. MN faces active hostile legislation (HF4142); Missouri has no hostile 2026 legislation.
• GLP-1 pricing index: brand, compounded, and cash-pay channels — Missouri’s verbatim Wegovy CWM exclusion creates a documented cash-pay pathway for Missouri MO HealthNet members and commercially-insured Missourians who cannot access semaglutide for chronic weight management through their coverage. Missouri is a positive-coverage state for Zepbound and Foundayo, but Wegovy-seeking patients who do not meet the MACE or MASH criteria have no covered semaglutide pathway and enter the cash-pay compounded or brand-name market this pricing index tracks.
• Foundayo vs Wegovy vs Zepbound: head-to-head comparison — Missouri is the only state in this series where the Foundayo vs Wegovy comparison has direct Medicaid-coverage stakes: Foundayo is Preferred; Wegovy is explicitly excluded for CWM. This comparison article covers the molecular differences (oral non-peptide GLP-1 vs subcutaneous semaglutide vs subcutaneous tirzepatide dual GIP/GLP-1), trial efficacy data, and the regulatory timelines that produced Missouri’s asymmetric PDL placement.
• State Medicaid GLP-1 coverage hub — all 22 verified states — Missouri is the 22nd state in this primary-source-verified series. The hub provides per-state pattern cards and a 50-state alphabetical grid.

Sources and last verified date

Last verified: 2026-05-10. Primary sources consulted: MO HealthNet Uniform PDL effective 2026-05-01 (XLSX, mydss.mo.gov); SmartPA Criteria Proposal (October 14, 2025 revision, PDF, mydss.mo.gov); PA Form 2575-053 (January 2026, PDF, mydss.mo.gov); DPAC Minutes January 20, 2026 (DOCX, approved, mydss.mo.gov); DPAC Minutes October 14, 2025 (PDF, approved, mydss.mo.gov); 42 U.S.C. § 1396r-8(d)(2)(A) (Cornell LII); 13 CSR 70-20.200 (Cornell LII); UnitedHealthcare Community Plan of Missouri provider documentation; KFF Medicaid GLP-1 tracker (January 2026 update); SB 1606 (senate.mo.gov); Children’s Mercy The Link newsletter (January 2025); KBIA Mizzou article (March 2026); MO HealthNet Hearings Manual (dssmanuals.mo.gov); SELECT trial (PMID 37952131); ESSENCE trial (PMID 40305701).

Coverage policies change. Verify current PDL status at mopdl.gainwelltechnologies.com and download the current Form 2575-053 from mydss.mo.gov before submitting any PA. The next DPAC meeting that may affect the GLP-1 obesity class is scheduled for July 2026 (next quarterly cycle after April 14, 2026).